Alivus Life Sciences announces acquisition of majority stake in IQGenX

M&A / JV 18 Aug 2026 · Announced· ✓ Verified

Alivus Life Sciences Limited, a BSE/NSE-listed entity, announced the acquisition of a majority stake in IQGenX through an official exchange-notified press release. The transaction was disclosed via the NSE archive on 18 August 2026. Exact consideration, percentage stake acquired, and deal conditions were not detailed in the headline announcement and require review of the full press release document and any subsequent exchange disclosures or company investor relations announcements.

Why it mattersListed acquirers in the life sciences space using majority stake structures must navigate SEBI takeover code thresholds, foreign investment clearances (if applicable), and integration compliance in a regulated pharma environment.
Counsel—
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object]

Sources

Open in the live tracker →

Related deals